Humira
Stock Recap #PipelineProspector

Pipeline Prospector 2023 highlights: Obesity drugs perk up Lilly, Novo sales; ADCs spur dealmaking

The year 2023 was marked by volatility. The good news is that despite factors like inflation, intere

Pipeline Prospector Oct 2023: Disappointing Q3 results, attacks on Israel, Gaza drag pharma indices down further

October was a gloomy month that saw Palestinian militant group Hamas attack Israel in the first week

Pipeline Prospector March 2023: Silicon Valley Bank collapse hits biotech indices; Pfizer buys out Seagen

Biotech indices have witnessed a lot of volatility throughout 2022 and 2023. Just when they were beg

Pipeline Prospector Jan 2023: Mega cap drugmakers face rout at bourses even as biotech indices inch upwards

After facing the worst year since 2008, biotech indices opened 2023 on a positive note. All the thre

Pipeline Prospector Feb 2022: Biotechs face cash crunch after stock market ‘bloodbath’

Our January 2022 update of the Pipeline Prospector highlighted how the Omicron variant of the novel